You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》野村上調石藥(01093.HK)目標價至12.32元 評級「買入」
阿思達克 03-23 11:35
野村發表研究報告,指石藥集團(01093.HK)去年收入及純利分別按年升11.7%及8.6%,較該行預期分別高2%及3%。管理層稱,經常性純利按年升24.2%至54億元人民幣。毛利率及經營溢利率各升0.9及0.5個百分點至分別75.8%及22.4%。 報告稱,去年第四季石藥銷售在低基數下按年升26.2%,純利亦跌22.6%,因經營開支上升,及缺乏單次性其他收益。該行升石藥今明兩年收入預測各2%,盈利預測分別上調6%及7%,料2021至2024年間盈利年均複合增長6%;以現金流折現率計,目標價由11.45元升至12.32元,維持「買入」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account